Biased usage of t cell receptor β-chain variable region genes of wilms' tumor gene (WT1)-specific CD8+ t cells in patients with solid tumors and healthy donors

Cancer Science

Volumn 103, Issue 3, 2012, Pages 408-414

  Morimoto, Soyoko ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Tanaka, Yukie ^b   Fujiki, Fumihiro ^a   Nakajima, Hiroko ^a   Hosen, Naoki ^a   Nishida, Sumiyuki ^a   Nakata, Jun ^a   Nakae, Yoshiki ^a   Maruno, Motohiko ^c   Myoui, Akira ^d   Enomoto, Takayuki ^a   Izumoto, Shuichi ^e   Sekimoto, Mitsugu ^a   Kagawa, Naoki ^a   Hashimoto, Naoya ^a   Yoshimine, Toshiki ^a   Oji, Yusuke ^a   Kumanogoh, Atsushi ^a   Sugiyama, Haruo ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HLA A ANTIGEN; EPITOPE; HLA A*02:01 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURGERY; CD8+ T LYMPHOCYTE; CECUM CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE FREQUENCY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; T LYMPHOCYTE RECEPTOR BETA CHAIN VARIABLE REGION GENE; T LYMPHOCYTE RECEPTOR GENE; TUMOR SUPPRESSOR GENE; ADOLESCENT; CELL SEPARATION; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; NEOPLASM;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENES, WILMS TUMOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84859698426     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02163.x     Document Type: Article

References (41)

1. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674-8.
2. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ 3rd, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995; 55: 5386-9.
3. Kim J, Prawitt D, Bardeesy N et al. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 1999; 19: 2289-99.
4. Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.
5. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-8.
6. Yamagami T, Sugiyama H, Inoue K et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878-84.
7. Inoue K, Tamaki H, Ogawa H et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-76.
8. Tsuboi A, Oka Y, Ogawa H et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
9. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-9.
10. Bergmann L, Miething C, Maurer U et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse longterm outcome. Blood 1997; 90: 1217-25.
11. Tamaki H, Ogawa H, Ohyashiki K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393-9.
12. Oji Y, Ogawa H, Tamaki H et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204.
13. Oji Y, Suzuki T, Nakano Y et al. Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 2004; 95: 822-7.
14. Oji Y, Yano M, Nakano Y et al. Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 2004; 24: 3103-8.
15. Cilloni D, Gottardi E, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-21.
16. Tamaki H, Mishima M, Kawakami M et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349-56.
17. Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-704.
18. Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
19. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLAA* 2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-20.
20. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000; 164: 1873-80.
21. Tsuboi A, Oka Y, Ogawa H et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000; 20: 195-202.
22. Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-9.
23. Wu F, Oka Y, Tsuboi A et al. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 2005; 19: 268-74.
24. Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001; 7: 761s-5s.
25. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
26. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101: 13885-90.
27. Kawakami M, Oka Y, Tsuboi A et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85: 426-9.
28. Kaida M, Morita-Hoshi Y, Soeda A et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011; 34: 92-9.
29. Rezvani K, Yong AS, Mielke S et al. Repeated PR1 and WT1 peptide vaccination in montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011; 96: 432-40.
30. Tanaka-Harada Y, Kawakami M, Oka Y et al. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci 2010; 101: 594-600.
31. Nakatsuka S, Oji Y, Horiuchi T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804-14.
32. Valmori D, Scheibenbogen C, Dutoit V et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7()) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002; 62: 1743-50.
33. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
34. Valmori D, Dutoit V, Liénard D et al. Tetramer-guided analysis of TCR betachain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol 2000; 165: 533-8.
35. Derré L, Bruyninx M, Baumgaertner P et al. In vivo persistence of codominant human CD8+ T cell clonotypes is not limited by replicative senescence or functional alteration. J Immunol 2007; 179: 2368-79.
36. Wadia P, Rao D, Pradhan T, Pathak A, Chiplunkar S. Impaired lymphocyte responses and their restoration in oral cancer patients expressing distinct TCR variable region. Cancer Invest 2008; 26: 471-80.
37. Dietrich PY, Walker PR, Quiquerez AL et al. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res 2001; 61: 2047-54.
38. Willhauck M, Möhler T, Scheibenbogen C et al. T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res 1996; 2: 767-72.
39. Mandruzzato S, Rossi E, Bernardi F et al. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 2002; 169: 4017-24.
40. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol 2004; 173: 7622-9.
41. Pospori C, Xue SA, Holler A et al. Specificity for the tumor-associated selfantigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood 2011; 117: 6813-24.